Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
Paul Hanna, Ian A. Strohbehn, Daiana Moreno, Destiny Harden, Rituvanthikaa Seethapathy, Rani Sawtell, Qiyu Wang, Tianqi Ouyang, Nurit Katz‐Agranov, James G. Dinulos, Seth A. Wander, Shruti Gupta, Meghan E. Sise
Abstract
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.
Topics & Concepts
Cyclin-dependent kinaseMedicineMetastatic breast cancerRenal functionBreast cancerAdverse effectInternal medicineOncologyKidneyCancerKinaseKidney cancerCancer researchBiologyCell cycleCell biologyAdvanced Breast Cancer TherapiesCancer-related cognitive impairment studiesChronic Lymphocytic Leukemia Research